IP Library Patent Application 11285537
Patent Application
App. No. 11/285,537

Modifying nicotine and nitrosamine levels in tobacco

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/285,537
Abstract

The present invention generally relates to tobacco and tobacco products having a reduced amount of nicotine and/or tobacco specific nitrosamines (TSNA). More specifically, several ways to make tobacco plants that have reduced nicotine and TSNA levels have been discovered. Embodiments include tobacco harvested from said tobacco plants, cured tobacco from said tobacco plants, tobacco products made with said cured tobacco and methods of making these compositions.

Claims (37)

1 . A tobacco product comprising a cured tobacco that comprises a genetic modification, wherein said tobacco product has a collective content of N′-nitrosonomicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) of less than 0.5 μg/g.

2 . The tobacco product of claim 1 , wherein said cured tobacco is of the genus Nicotiana.

3 . The tobacco product of claim 2 , wherein said cured tobacco is selected from the group consisting of Burley, Flue, and Oriental.

4 . The tobacco product of claim 2 , wherein said cured tobacco is Burley.

5 . The tobacco product of claim 2 , wherein said cured tobacco is Flue.

6 . The tobacco product of claim 1 , wherein said cured tobacco comprises an exogenous nucleic acid that encodes an enzyme in the nicotine synthesis pathway or a fragment thereof at least 25 nucleotides in length.

7 . The tobacco product of claim 1 , wherein said cured tobacco comprises a fragment of a nucleic acid that encodes an enzyme in the nicotine synthesis pathway that is at least 50 nucleotides in length.

8 . The tobacco product of claim 1 , wherein said cured tobacco comprises a fragment of a nucleic acid that encodes an enzyme in the nicotine synthesis pathway that is at least 100 nucleotides in length.

9 . The tobacco product of claim 1 , wherein said cured tobacco comprises a fragment of a nucleic acid that encodes an enzyme in the nicotine synthesis pathway that is at least 250 nucleotides in length.

10 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 11 mg/g.

11 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 9 mg/g.

12 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 7 mg/g.

13 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 5 mg/g.

14 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 3 mg/g.

15 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 2 mg/g.

16 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 1 mg/g.

17 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 0.7 mg/g.

18 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 0.5 mg/g.

19 . The tobacco product of claim 1 , wherein the amount of nicotine in said product is less than 0.1 mg/g.

20 . The tobacco product of claim 1 , wherein the collective content of N′-nitrosonomicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) is less than 0.4 μg/g.

21 . The tobacco product of claim 1 , wherein the collective content of N′-nitrosonomicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) is less than 0.3 μg/g.

22 . The tobacco product of claim 1 , wherein the collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) is less than 0.2 μg/g.

23 . The tobacco product of claim 1 , wherein the collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) is less than 0.1 μg/g.

24 . The tobacco product of claim 1 , wherein the collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) is less than 0.05 μg/g.

25 . The tobacco product of claim 1 , wherein the collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) is less than 0.02 μg/g.

26 . The tobacco product of claim 1 , wherein the collective content of N′-nitrosonornicotine (NNN), N′-nitrosoanatabine (NAT), N′-nitrosoanabasine (NAB), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) is less than 0.01 μg/g.

27 . The tobacco product of claim 6 , wherein said enzyme in the nicotine synthesis pathway is selected from the group consisting of putrescine N-methyltransferase, N-methylputrescine oxidase, ornithine decarboxylase, S-adenosylmethionine synthetase, NADH dehydrogenase, phosphoribosylanthranilate isomerase, and quinolate phosphoribosyl transferase.

28 . The tobacco product of claim 7 , wherein said enzyme in the nicotine synthesis pathway is selected from the group consisting of putrescine N-methyltransferase, N-methylputrescine oxidase, ornithine decarboxylase, S-adenosylmethionine synthetase, NADH dehydrogenase, phosphoribosylanthranilate isomerase, and quinolate phosphoribosyl transferase.

29 . The tobacco product of claim 8 , wherein said enzyme in the nicotine synthesis pathway is selected from the group consisting of putrescine N-methyltransferase, N-methylputrescine oxidase, ornithine decarboxylase, S-adenosylmethionine synthetase, NADH dehydrogenase, phosphoribosylanthranilate isomerase, and quinolate phosphoribosyl transferase.

30 . The tobacco product of claim 9 , wherein said enzyme in the nicotine synthesis pathway is selected from the group consisting of putrescine N-methyltransferase, N-methylputrescine oxidase, ornithine decarboxylase, S-adenosylmethionine synthetase, NADH dehydrogenase, phosphoribosylanthranilate isomerase, and quinolate phosphoribosyl transferase.

31 . The tobacco product of claim 1 , wherein said tobacco product is a cigarette.

32 . The tobacco product of claim 6 , wherein said tobacco product is a cigarette.

33 . The tobacco product of claim 10 , wherein said tobacco product is a cigarette.

34 . The tobacco product of claim 15 , wherein said tobacco product is a cigarette.

35 . The tobacco product of claim 18 , wherein said tobacco product is a cigarette.

36 . The tobacco product of claim 22 , wherein said tobacco product is a cigarette.

37 . The tobacco product of claim 25 , wherein said tobacco product is a cigarette.

Assignments (5)
RELEASE OF PATENT SECURITY AGREEMENT [AT REEL/FRAME NO. 19704/0442] Recorded Feb 12, 2013
From: U.S. BANK NATIONAL ASSOCIATION
To: VECTOR TOBACCO INC.
Reel/Frame 029794/0397 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2009
From: U.S. BANK NATIONAL ASSOCIATION
To: VECTOR GROUP LTD.
Reel/Frame 022256/0433 →
PATENT SECURITY AND PLEDGE AGREEMENT Recorded Aug 16, 2007
From: VECTOR TOBACCO INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 019704/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2007
From: VECTOR TOBACCO LTD.
To: VECTOR TOBACCO INC.
Reel/Frame 019600/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2006
From: CONKLING, MARK A.
To: VECTOR TOBACCO (USA) LTD.
Reel/Frame 018187/0451 →